Vecta Ltd.: Clinical Trials

1 trial sponsored by Vecta Ltd., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Completed 1

Follow Vecta Ltd.: new trials by email

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms
VECAM 40/300, Esomeprazole 20 mg - Gastroesophageal Reflux
Phase 2CompletedVecta Ltd.522009-12-012012-07-30

Conditions studied

Gastroesophageal Reflux (1)  ·  Heartburn (1)

Interventions

Esomeprazole (1)

Countries

United States (1)